A Dialysis Membrane-Integrated Microfluidic Device for Controlled Drug Retention and Nutrient Supply
Open Access
- 25 June 2025
- journal article
- research article
- Published by MDPI AG in Micromachines
- Vol. 16 (7) , 745
Abstract
Traditional pre-clinical drug evaluation methods, including animal experiments and static cell cultures using human-derived cells, face critical limitations such as interspecies differences, ethical concerns, and poor physiological relevance. More recently, microphysiological systems (MPSs) that use microfluidic devices to mimic in vivo conditions have emerged as promising platforms. By enabling perfusion cell culture and incorporating human-derived cells, MPSs can evaluate drug efficacy and toxicity in a more human-relevant manner. However, standard MPS protocols rely on discrete medium changes, causing abrupt changes in drug concentrations that do not reflect the continuous pharmacokinetics seen in vivo. To overcome this limitation, we developed a Dialysis Membrane-integrated Microfluidic Device (DMiMD) which maintains continuous drug concentrations through selective medium change via a dialysis membrane. The membrane’s molecular weight cut-off (MWCO) enables the retention of high-molecular-weight drugs while facilitating the passage of essential low-molecular-weight nutrients such as glucose. We validated the membrane’s molecular selectivity and confirmed effective nutrient supply using cells. Additionally, anticancer drug efficacy was evaluated under continuously changing drug concentrations, demonstrating that the DMiMD successfully mimics in vivo drug exposure dynamics. These results indicate that the DMiMD offers a robust in vitro platform for accurate assessment of drug efficacy and toxicity, bridging the gap between conventional static assays and the physiological complexities of the human body.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP18H01849, JP24K01321, JP17be0304201, JP22be1004201)
- Japan Agency for Medical Research and Development (JP18H01849, JP24K01321, JP17be0304201, JP22be1004201)
This publication has 28 references indexed in Scilit:
- Advancements in Microphysiological systems: Exploring organoids and organ-on-a-chip technologies in drug development -focus on pharmacokinetics related organs-Drug Metabolism and Pharmacokinetics, 2024
- Multi‐Organ Microphysiological Systems Targeting Specific Organs for Recapitulating Disease Phenotypes via Organ CrosstalkSmall Science, 2024
- Microphysiological systems for realizing microenvironment that mimics human physiology—functional material and its standardization applied to microfluidicsEmergent Materials, 2024
- Diffusion of glucose in water: A molecular dynamics studyJournal of Molecular Liquids, 2022
- The potential of multi-organ-on-chip models for assessment of drug disposition as alternative to animal testingCurrent Opinion in Toxicology, 2021
- Organ/body-on-a-chip based on microfluidic technology for drug discoveryDrug Metabolism and Pharmacokinetics, 2018
- Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancerInternational Journal of Pharmaceutics, 2014
- Simultaneous online SPE–HPLC–MS/MS analysis of docetaxel, temsirolimus and sirolimus in whole blood and human plasmaJournal of Chromatography B, 2013
- Three-dimensional cell culture: the missing link in drug discoveryDrug Discovery Today, 2013
- Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxelClinical Pharmacology & Therapeutics, 2004